Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study

[1]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[2]  M.F. Madu,et al.  Sentinel node biopsy in melanoma: Current controversies addressed. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[4]  C. Berking,et al.  Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[5]  E. Bastiaannet,et al.  The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  Farzad Hadaegh,et al.  A tutorial on variable selection for clinical prediction models: feature selection methods in data mining could improve the results. , 2016, Journal of clinical epidemiology.

[7]  H. Qu,et al.  Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes , 2015, World Journal of Surgical Oncology.

[8]  S. Mocellin,et al.  Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Elashoff,et al.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. , 2014, The New England journal of medicine.

[10]  S. Mocellin,et al.  Interferon alpha for the adjuvant treatment of cutaneous melanoma. , 2013, The Cochrane database of systematic reviews.

[11]  R. Scolyer,et al.  Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes , 2013, Pigment cell & melanoma research.

[12]  H. Kang,et al.  Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients. , 2011, Oncology reports.

[13]  R. Scolyer,et al.  Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Mocellin,et al.  Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI) , 2009, Annals of Surgical Oncology.

[15]  Jeffrey E. Lee,et al.  Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Royston,et al.  Selection of important variables and determination of functional form for continuous predictors in multivariable model building , 2007, Statistics in medicine.

[18]  Christopher H. Schmid,et al.  Multivariate Classification Rules: Calibration and Discrimination , 2005 .

[19]  Jennifer L. Schwartz,et al.  Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. , 2005, Journal of the American College of Surgeons.

[20]  D. Morton,et al.  Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Navarro,et al.  XPD, XPA, ERCC1 and XPG/ERCC5 single nucleotide polymorphisms (SNPs) in oxaliplatin-treated colorectal cancer (CRC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[23]  J. Ouellet,et al.  Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients. , 2016, American journal of surgery.